SCHEMBL6575282

SCHEMBL6575282

CCOC(=O)C(OC(=O)OC1CC2CCC(C1)N2C)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.59
CYP2D6 P10635 3/20 0.59
CYP2C9 P11712 1/20 0.59
HSD17B10 Q99714 1/20 0.59
CHRM2 P08172 6/20 0.59
CHRM1 P11229 6/20 0.59
CHRM3 P20309 6/20 0.59
CHRM5 P08912 5/20 0.59
CHRM4 P08173 4/20 0.59
HTR2C P28335 3/20 0.59
BLM P54132 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
ADRA2C P18825 2/20 0.59
ADRA1A P35348 2/20 0.59
HRH1 P35367 2/20 0.59
ADRA1D P25100 2/20 0.59
KDM4E B2RXH2 1/20 0.59
POLB P06746 1/20 0.59
NFKB1 P19838 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6577643 0.83 CHRM2 (0.60) CHRM2CHRM1CHRM3CHRM5CHRM4
SCHEMBL9493619 0.80 LMNA (0.60) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL23494957 0.77 CHRM1 (0.81) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL13176563 0.77 CHRM1 (0.81) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL23494955 0.77 CHRM1 (0.81) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL17430025 0.77 CHRM1 (0.81) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL250617 0.76 LMNA (0.77) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL8872524 0.76 LMNA (0.77) LMNACYP2D6CYP2C9HSD17B10CHRM2
SCHEMBL6574291 0.75 CHRM3 (0.54) CYP2D6CHRM2CHRM1CHRM3CHRM5
SCHEMBL23494998 0.75 CYP2D6 (0.76) LMNACYP2D6CYP2C9HSD17B10CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP claimed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO claimed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US claimed
EP-1383730-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE Aryx Therapeutics (US) 2004-01-28 EP disclosed
WO-2002096855-A2 ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE ARYX THERAPEUTICS (US) 2002-12-05 WO disclosed
US-20020169208-A1 Novel anticholinergic compounds and methods of use ARYX THERAPEUTICS 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169208-A1 Novel anticholinergic compounds and methods of use CHRM3, CHRM5, CHRM2 LMNA 3712/4885CYP2D6 1150/4885CYP2C9 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.